Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) and Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.
Risk and Volatility
Neuphoria Therapeutics has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.19, indicating that its share price is 119% less volatile than the S&P 500.
Earnings & Valuation
This table compares Neuphoria Therapeutics and Entrada Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neuphoria Therapeutics | $1.17 million | 11.93 | -$13.45 million | ($6.22) | -0.41 |
| Entrada Therapeutics | $25.42 million | 7.96 | -$143.75 million | ($3.84) | -1.35 |
Neuphoria Therapeutics has higher earnings, but lower revenue than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Neuphoria Therapeutics and Entrada Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neuphoria Therapeutics | N/A | -38.31% | -28.92% |
| Entrada Therapeutics | -4,057.98% | -64.00% | -50.49% |
Analyst Ratings
This is a breakdown of current ratings for Neuphoria Therapeutics and Entrada Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neuphoria Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
| Entrada Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
Neuphoria Therapeutics currently has a consensus target price of $7.00, indicating a potential upside of 171.32%. Entrada Therapeutics has a consensus target price of $17.75, indicating a potential upside of 243.33%. Given Entrada Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Entrada Therapeutics is more favorable than Neuphoria Therapeutics.
Insider & Institutional Ownership
15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Entrada Therapeutics beats Neuphoria Therapeutics on 7 of the 13 factors compared between the two stocks.
About Neuphoria Therapeutics
Neuphoria Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and psychiatric disorders. Its work is directed toward addressing significant unmet medical needs in central nervous system medicine. The company is advancing an investigational pipeline of therapeutic candidates and is primarily engaged in pharmaceutical research and development. Publicly available information does not provide sufficient detail to reliably identify specific marketed products, served geographies, or the company’s current leadership.
About Entrada Therapeutics
Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.
Receive News & Ratings for Neuphoria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
